We are a network of UK academic experts with real world experience of translating human pluripotent stem cell (hPSC)-derived cell therapies to the clinic. Established under the UK Regenerative Medicine Platform in 2018, Regen CTC’s members include fundamental scientists, manufacturing engineers, clinicians and expert translational scientists with experience in developing quality management systems, clean room operations and process development of research protocols.


Zoe Hewitt

Co-Founder and CEO and Quality Management Specialist

Zoe has over 20 years of experience working with human Pluripotent Stem Cells. After obtaining her PhD from the Roslin Institute, Edinburgh in 2006, she moved to the Centre for Stem Cell Biology at the University of Sheffield where she was handed a newly built clean room facility and was asked to “make it work”. With over 15 years of experience developing Quality Management Systems, operating within a clean room environment and assisting with the early stages of cell therapy development, including with the UKs first-in-human clinical trial with a human embryonic stem cell derived therapy for Macular degeneration, Zoe’s focus is on sharing this experience with the wider regenerative medicine community to assist more therapies to make it to clinical trial, so that patients can receive their benefits.

Zoe was behind the team who derived the UKs first available clinical grade embryonic stem cell lines, has been an integral part of the UK Regenerative Medicine Platform since its inception and represented the field on the British Standards Institute committee for Regenerative Medicine. She also undertook an active role working with regulators at the HFEA, HTA and MHRA to resolve early regulatory issues which surround the translation of stem cells to clinical application, particularly when the European Union Tissue and Cell Directives were first introduced in 2005.

Roger Barker 

Co-Founder and Chair and Clinical Specialist

Roger is a Professor of Clinical Neuroscience at the University of Cambridge and a consultant Neurologist at the Addenbrooke’s Hospital. He has also been a director or lead investigator on a number of significant regenerative medicine focused initiatives such as GFORCEPD, STEMPD, the UK Regenerative Medicine Platform (UKRMP), Pluripotent Stem Cell and Engineered Cell (PSEC) Hub, the International Society for Stem Cell research (ISSCR) and is the current Lead Academic Scientist of the ARUK funded Drug Discovery Institute in Cambridge.

His research group is focused on better defining the clinical heterogeneity of two common neurodegenerative disorders of the nervous system – Parkinson’s disease (PD) and Huntington’s disease (HD). This has helped him define the best way by which to take new therapies including novel experimental therapeutics such as cell and gene therapies into the clinic.


Ivana Barbaric

Fundamental Scientist – Specialising in Genetic Stability

Ivana is a Professor in Stem Cell Biology within the Centre for Stem Cell Biology at the University of Sheffield. Her research focuses on the genetic stability of human Pluripotent Stem Cells (hPSCs), the extrinsic and intrinsic cues that govern the stem cell fates, and using hPSCs for disease modelling and drug discovery.

With her extensive expertise in this area, Ivana has been appointed to the International Society for Stem Cell Research (ISSCR) Task Force on Standards in Stem Cell Research; co-chairing the working group on Genomic characterisation of stem cells. She has also been appointed to the steering committee for the International Stem Cell Initiative (ISCI) and is a member of the ISCI Genetics and Epigenetics Study Group.

Cedric Ghevaert

Clinical Specialist

Cedric is a Professor in Transfusion Medicine at the University of Cambridge and a consultant haematologist for the NHS Blood and Transplant Service. His research is focused on the production of blood cells in vitro with a particular interest in platelet and megakaryocyte biology. His group has developed expertise in the production of red cells and platelets from human pluripotent stem cells using methodologies that are compatible with the production of clinical grade products within the constraints of affordable manufacturing processes.

As a consultant haematologist, Cedric is the clinical lead for a first-in human study of stem cell-derived red blood cell survival and recovery in human volunteers. He has also recently secured a place on the prestigious NHS-funded “National Clinical Entrepreneur” programme and been made a Champion for the Department of Haematology at the Cambridge Academy for Translational Science.

Florian Merkle

Fundamental Scientist – Specialising in the Mechanistic basis of Neurological Diseases

Florian leads a research group at the University of Cambridge as a New York Stem Cell Foundation Robertson Stem Cell Investigator and Sir Henry Dale Fellow. His research aims to uncover the mechanistic basis of human neurological diseases using human pluripotent stem cell (hPSC)-derived culture systems in order to facilitate the development of effective treatments. Specifically, his group generates novel differentiation strategies to produce a variety of neural cell types, and develops cellular and animal models of metabolic and neurodegenerative disease. He also helped uncover recurrently acquired structural genetic variants and point mutations in hPSCs, including in the tumour suppressor p53.
Florian is therefore also interested in the rational selection of hPSC lines and identifying strategies to suppress the expansion of undesired mutations in vitro in order to improve the reproducibility of fundamental research and the safety of translational approaches.

Wolf Reik

Fundamental Scientist – Specialising in Epigenetics

Wolf is an MD, an honorary Professor of Epigenetics at the Babraham Institute and the University of Cambridge and Fellow of the Royal Society. His research interests are in mammalian epigenetics, particularly in epigenetic reprogramming during mammalian development and its role in stem cell biology, inheritance and ageing.
Recently Wolf left his position as Director of the Babraham Institute to become Director of the Altos Labs Cambridge Institute of Science.  

Robert Thomas

Manufacturing Specialist

Rob is a Professor of Manufacturing for Cell and Gene Therapies at Loughborough University and a RCUK Academic Fellow (Biomanufacturing). He is also Founder and Managing Director of Advanced Bioprocess Services Limited and Scientific Lead at Safi Biosolutions.
Rob’s research focuses on the development of scientific and engineering solutions for cell-based therapy manufacture, engaging in both academic funded projects and provision of commercial process development services (via Advanced Bioprocess Services Ltd). In particular, he looks to address the challenges of scalability whilst improving control of product quality and cost of goods.

Regen CTC

© 2022 RegenCTC
All Rights Reserved

Company No: 14114625

Privacy Policy

Our Location

The Innovation Centre, 217 Portobello, Sheffield, S1 4DP
0114 3767 282

Stay in touch